Aris Water Solutions (NYSE:ARIS) Hits New 52-Week High at $17.95

Kymera Therapeutics' (KYMR) "Buy" Rating Reiterated at Truist Financial



Truist Financial restated a “buy” rating and set a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday.



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *